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 Moving the needle on neonatal and child health
Babies and children feature heavily in this August issue 
of The Lancet Global Health, as well they should at a time 
when unﬁ nished agendas are top of the agenda. In its 
2014 report on the Millennium Development Goals, 
released on July 7, the UN described the under-5 mortality 
goal as “slipping away from achievement by 2015”. The 
research and opinion in this month’s issue harnesses a 
variety of diﬀ erent angles from which to “move the needle” 
on neonatal and child health. How can we ensure that 
neonatal interventions reach the very poorest families who 
need them the most? Are we doing enough for children 
with tuberculosis? What is the role of malaria in low 
birthweight? And are there any unintended adverse con-
sequences of the introduction of new vaccines in Africa?
In their Comment, Tanja Houweling and colleagues 
attack the ﬁ rst question on the back of the launch on 
June 30 of the Every Newborn Action Plan. The plan called 
for investment in perinatal care, better quality of care, 
greater access, community engagement, and better data 
collection and management. In order to realise these 
objectives, Houweling and colleagues advocate for greater 
use of women’s participatory groups—whereby women 
themselves identify and prioritise problems during 
pregnancy, delivery, and post partum, and then plan and 
implement locally feasible strategies to address them. 
Such groups are well placed to identify and inform the 
lowest-income families and to empower them to demand 
respectful, high-quality care. Alone, however, they cannot 
tackle the problems of underinvestment, substandard 
medical education, and poor regulation that can only be 
solved with the help of our old friend political will.
Both political and private-sector will come into play in 
the question of paediatric tuberculosis. In their modelling 
study, Peter Dodd and colleagues estimate that the burden 
of tuberculosis is about 25% higher than previously 
thought. Looking at the 22 countries that account for 
80% of the world’s burden of tuberculosis, they estimate 
that around 650 000 children developed the disease in 
2010. A comparison with oﬃ  cial notiﬁ cations suggested 
that the case detection rate for children was a mere 35% 
(compared with 66% for adults). National programmes 
are clearly failing children, and diagnostic tests and 
treatment regimens for this age group still lag behind 
those for adults. Dodd and colleagues are hopeful that 
careful estimation of the burden of tuberculosis in children 
can spur action. As Dodd stated in a press release to 
accompany the paper, “without good numbers, there can 
be no targets for improvement, no monitoring of trends; 
and there is a lack of evidence to encourage industry to 
invest in developing medicines or diagnostics that are 
more appropriate for children than those available today.” 
The biggest single cause of child mortality is preterm 
birth, and infection during pregnancy is an important 
risk factor for that. In their Article, Patrick Walker and 
colleagues use mathematical modelling to estimate the 
burden of low birthweight (due to either preterm birth 
or intrauterine growth restriction) caused by malaria in 
Africa. They calculate that, without pregnancy-speciﬁ c 
protection, a woman in Africa has a roughly 50-50 chance 
of being exposed to malaria infection during pregnancy, 
and a one in ﬁ ve chance of developing placental infection. 
This ﬁ gure relates to 900 000 entirely preventable low 
birthweight deliveries per year. Since most transmission 
occurs before or early in pregnancy, Walker and colleagues 
recommend synergy between malaria prevention pro-
grammes and antenatal and family planning programmes 
and rightly call for protection of pregnant women from 
malaria to be made a public-health priority. 
Joined-up thinking is also a lesson that emerges 
from Ane Fiske and colleagues’ observational study in 
Guinea-Bissau. In their Article, they describe a decrease 
in measles vaccine coverage by 12 months of age after 
the introduction of pentavalent vaccine (diphtheria, 
tetanus, pertussis, Haemophilus inﬂ uenzae type b, and 
hepatitis B). What went wrong? The answer probably lies 
in a concurrent decision to introduce a stricter wastage 
policy and to focus on vaccination by 12 months of age. 
These policies, which were instigated in response to GAVI 
guidance but which were not in themselves proposed by 
GAVI, seem to have resulted in vaccinators not opening 
any ten-dose vials of measles vaccine unless at least six 
children were present. Some children’s vaccinations thus 
seem to have been delayed until they passed 12 months, 
after which they no longer became a priority age group. 
Be sure to read the rest of the issue for more varied 
and thought-provoking analysis of eﬀ orts to keep a grip 
on the slippery goal of MDG5.
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